Literature DB >> 34150437

Effects of short-term calorie restriction on circulating DPP-4/sCD26 concentrations and body composition in patients with type 2 diabetes.

Mototaka Yamauchi1, Takafumi Tsuchiya1, Kohzo Takebayashi1, Toshihiko Inukai1,2, Koshi Hashimoto1.   

Abstract

Previous studies have shown that dipeptidyl peptidase (DPP)-4, is released from adipocytes in a differentiation-dependent manner and a marker for insulin resistance in obese individuals who have particularly high circulating DPP-4/soluble CD26 (sCD26) concentrations. In this study, we have evaluated the effects of short-term hospitalization with calorie restriction on body composition and circulating DPP-4/sCD26 concentrations in patients with type 2 diabetes. A total of 47 Japanese adults with type 2 diabetes were recruited to the study (age; 56.6 ± 13.0 years, body mass index (BMI); 27.3 ± 5.6 kg/m2). Body composition, circulating DPP-4/sCD26 concentrations and metabolic parameters were assessed upon admission and at discharge from hospital (average of the period: 13.0 ± 2.5 days). Visceral fat area (VFA) was also assessed by dual impedance method. During hospitalization, there was a significant reduction in body weight, BMI, lean body mass, VFA and circulating DPP-4/sCD26 concentrations, but not in body fat mass. Fasting circulating DPP-4/sCD26 concentrations were significantly correlated with fasting insulin, aspartate aminotransferase, γ-glutamyltransferase (γ-GTP) levels, and HOMA-IR (r = 0.477, 0.423, 0.415, 0.548, respectively), but not with VFA (r = - 0.056) by liner regression analyses at base line. It was also observed a positive correlation between changes in circulating DPP-4/sCD26 concentrations and γ-GTP level, HOMA-IR, and a negative correlation between the changes in circulating DPP-4/sCD26 concentrations and VFA significantly (r = 0.300, 0.633, - 0.343, respectively). In conclusion, our observations suggest that liver enzymes as well as VFA might be associated with the response of DPP-4/sCD26 concentrations. © The Japan Diabetes Society 2021.

Entities:  

Keywords:  Body composition; DPP-4; Soluble CD26; Type 2 diabetes; Visceral fat

Year:  2021        PMID: 34150437      PMCID: PMC8172695          DOI: 10.1007/s13340-020-00485-z

Source DB:  PubMed          Journal:  Diabetol Int        ISSN: 2190-1678


  28 in total

1.  The utility of dual bioelectrical impedance analysis in detecting intra-abdominal fat area in obese patients during weight reduction therapy in comparison with waist circumference and abdominal CT.

Authors:  Hajime Yamakage; Ryo Ito; Mayu Tochiya; Kazuya Muranaka; Masashi Tanaka; Yoshiyuki Matsuo; Shinji Odori; Shigeo Kono; Akira Shimatsu; Noriko Satoh-Asahara
Journal:  Endocr J       Date:  2014-06-13       Impact factor: 2.349

2.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06

3.  Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.

Authors:  Yoshimasa Aso; Kanako Kato; Shintaro Sakurai; Haruka Kishi; Masanori Shimizu; Teruo Jojima; Toshie Iijima; Yuko Maejima; Kenju Shimomura; Isao Usui
Journal:  Int J Clin Pract       Date:  2019-04-01       Impact factor: 2.503

4.  Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance.

Authors:  D E Kelley; F L Thaete; F Troost; T Huwe; B H Goodpaster
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-05       Impact factor: 4.310

5.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

6.  Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice.

Authors:  S Mentzel; H B Dijkman; J P Van Son; R A Koene; K J Assmann
Journal:  J Histochem Cytochem       Date:  1996-05       Impact factor: 2.479

Review 7.  Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.

Authors:  Y G Kim; S Hahn; T J Oh; S H Kwak; K S Park; Y M Cho
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

8.  Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance.

Authors:  Stacey L Conarello; Zhihua Li; John Ronan; Ranabir Sinha Roy; Lan Zhu; Guoqiang Jiang; Franklin Liu; John Woods; Emanuel Zycband; David E Moller; Nancy A Thornberry; Bei B Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-14       Impact factor: 11.205

9.  Effects of Aging on Visceral and Subcutaneous Fat Areas and on Homeostasis Model Assessment of Insulin Resistance and Insulin Secretion Capacity in a Comprehensive Health Checkup.

Authors:  Hiroshi Hirose; Michiyo Takayama; Yasushi Iwao; Hiroshi Kawabe
Journal:  J Atheroscler Thromb       Date:  2015-09-28       Impact factor: 4.928

10.  Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.

Authors:  Henrike Sell; Matthias Blüher; Nora Klöting; Raphaela Schlich; Miriam Willems; Florian Ruppe; Wolfram Trudo Knoefel; Arne Dietrich; Barbara A Fielding; Peter Arner; Keith N Frayn; Jürgen Eckel
Journal:  Diabetes Care       Date:  2013-10-15       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.